A high drug failure rate is more than just a pattern recognition problem. Here's how we can address some of the root causes.

Merck's latest earnings call revealed a mix of growth and pain points for the pharmaceutical giant.

CNBC’s Deirdre Bosa, Big Technology’s Alex Kantrowitz and Wealth Enhancement’s Ayako Yoshioka, join 'Closing Bell' to discuss ...

Emily Field, head of European pharmaceuticals research at Barclays, weighs in on rising competition in the global obesity ...

There is growing enthusiasm about China’s potential to speed up drug development with AI. And companies outside the country ...

Hundreds of thousands of doses of moxidectin – which treats a disease caused by a parasitic worm – are being given to ...

Conduit and Sarborg complete all milestones of Phase I of their AI-driven drug development collaboration, and commence transitioning to Phase II, ...

I’m perfectly happy for the wizards to help me out in drug development and help speed medicines to […] the right patients,” he said. Oncology researcher Pierce works at Owkin, a Paris-based ...

New heart health biopharmaceutical company Kardigan, which counts among its co-founders the director for Northwestern ...

In this Pharmaceutical Executive video interview, Edoardo Madussi, Head of Business Development, Intelligencia AI discusses ...

Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were taking Wegovy ...